Farzan Nima

SEC Form 4 insider trading activity

Farzan Nima has filed 2 SEC Form 4 filings (2 transaction rows) across 1 company, with disclosures dating back to 2026. 2 of those filings fall inside the rolling window. Most recent filing: Jun 8, 2026.

On the most recent filing, Farzan Nima is listed as Director at Keros Therapeutics, Inc. Inside the rolling window, Farzan Nima reported no open-market purchases and 1 open-market sale totaling $28K in KROS.

Companies traded

Other insiders at KROS

Insider Buying

$0

reported purchases (SEC code P)

Insider Selling

$28K

reported sales (SEC code S)

Companies

1

in the rolling window

Source
KROS
Farzan Nima
Sale$28KJun 8SEC ↗
Showing 1–1 of 1
1 / 1

Frequently asked questions

How many SEC Form 4 filings has Farzan Nima made?

Farzan Nima has filed 2 SEC Form 4 filings (2 transaction rows) across 1 company since 2026.

Which companies does Farzan Nima trade?

Farzan Nima has filed SEC Form 4 disclosures for 1 company, including KROS.

When was Farzan Nima's most recent SEC Form 4 filing?

Farzan Nima's most recent SEC Form 4 filing on Tracefour is dated Jun 8, 2026.

What is Farzan Nima's total buy and sell value in the current window?

Inside the rolling retention window, Farzan Nima bought $0 and sold $28K based on SEC Form 4 filings.

What was Farzan Nima's largest disclosed transaction?

The largest disclosed transaction in the current window is a sale of 2,625 KROS shares on 2026-06-04, worth $28K, per SEC Form 4 filings.